TIL Stock Forecast: Instil Bio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Instil Bio, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 48 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Instil Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Momentum (10): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TIL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TIL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Jan 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 11 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2025 | JMP Securities | Reiterates | Market Perform | — |
| 23 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Feb 2025 | JMP Securities | Reiterates | Market Perform | — |
| 7 Jan 2025 | Jefferies | Upgrade | Buy | — |
| 18 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Nov 2024 | JMP Securities | Initiates | Market Perform | — |
| 17 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Sept 2024 | Baird | Reiterates | Outperform | — |
| 16 Sept 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Sept 2024 | Baird | Maintains | Outperform | — |
| 12 Sept 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TIL.
This page is one stock. Monday covers all of them.
TIL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TIL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Instil Bio, Inc. returned −56.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TIL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.3×
- EV / EBITDA
- —
Cheaper than 91% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −25.3%
- Return on assets
- −10.8%
- Dividend yield
- —
Higher than 30% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Instil Bio, Inc. has a market value of $37.6M and an enterprise value of $56.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$30.3M.
Free cash flow in the twelve months to 30 June 2026: −$33.6M.
Instil Bio, Inc. employs 17 people.
Data provided by Twelve Data
TIL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TIL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Instil Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TIL
What is the TIL stock price forecast for 2026-2027?
The median 12-month analyst price target for Instil Bio, Inc. is $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TIL stock a buy right now?
Of the 1 analyst covering Instil Bio, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Instil Bio, Inc. 48 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TIL?
As at 21 Nov 2026, Instil Bio, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
Will TIL stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $7, and Ticker Nerd's factor model ranks Instil Bio, Inc. 48 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TIL stock forecast for 2030?
No analyst covering Instil Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TIL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.
How has TIL stock performed over the past year?
Instil Bio, Inc. returned -56.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Instil Bio, Inc. do?
Instil Bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer. The company’s current work centers on tumor-infiltrating lymphocyte, or TIL, cell therapies designed to harness a patient’s own immune cells to attack solid tumors.
About Instil Bio, Inc.
Instil Bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer. The company’s current work centers on tumor-infiltrating lymphocyte, or TIL, cell therapies designed to harness a patient’s own immune cells to attack solid tumors. Its pipeline also includes next-generation programs built around engineered TIL approaches and bispecific antibody candidates aimed at difficult-to-treat cancers. Instil Bio Inc. operates as a research-driven biotechnology business, combining cell therapy development, manufacturing expertise, and clinical-stage oncology programs to address areas of significant unmet medical need. Headquartered in Dallas, Texas, the company plays a specialized role in the oncology market through its focus on advanced immunotherapy platforms and novel therapeutic candidates.
CEO Mr. Bronson Crouch · 17 employees · United States · https://instilbio.com